WallStSmart

Im Cannabis Corp (IMCC)vsViatris Inc (VTRS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Viatris Inc generates 32075% more annual revenue ($14.74B vs $45.80M). VTRS leads profitability with a -2.8% profit margin vs -39.1%. VTRS earns a higher WallStSmart Score of 48/100 (D+).

IMCC

Avoid

31

out of 100

Grade: F

Growth: 3.3Profit: 2.0Value: 5.0Quality: 4.5
Piotroski: 3/9Altman Z: -11.55

VTRS

Hold

48

out of 100

Grade: D+

Growth: 2.7Profit: 3.5Value: 4.3Quality: 5.0
Piotroski: 4/9Altman Z: 0.55
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for IMCC.

VTRSSignificantly Overvalued (-84.5%)

Margin of Safety

-84.5%

Fair Value

$8.74

Current Price

$16.95

$8.21 premium

UndervaluedFair: $8.74Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IMCC1 strengths · Avg: 10.0/10
Debt/EquityHealth
-2.5010/10

Conservative balance sheet, low leverage

VTRS1 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Areas to Watch

IMCC4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$984,3903/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-119.8%2/10

ROE of -119.8% — below average capital efficiency

VTRS4 concerns · Avg: 2.5/10
Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Return on EquityProfitability
-2.9%2/10

ROE of -2.9% — below average capital efficiency

EPS GrowthGrowth
-70.6%2/10

Earnings declined 70.6%

Altman Z-ScoreHealth
0.552/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : IMCC

The strongest argument for IMCC centers on Debt/Equity.

Bull Case : VTRS

The strongest argument for VTRS centers on Price/Book. PEG of 1.05 suggests the stock is reasonably priced for its growth.

Bear Case : IMCC

The primary concerns for IMCC are EPS Growth, Market Cap, Piotroski F-Score.

Bear Case : VTRS

The primary concerns for VTRS are Revenue Growth, Return on Equity, EPS Growth.

Key Dynamics to Monitor

IMCC carries more volatility with a beta of 2.10 — expect wider price swings.

VTRS is growing revenue faster at 4.9% — sustainability is the question.

VTRS generates stronger free cash flow (329M), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.

Bottom Line

VTRS scores higher overall (48/100 vs 31/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Im Cannabis Corp

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

IM Cannabis Corp. The company is headquartered in Tel Aviv-Yafo, Israel.

Visit Website →

Viatris Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.

Visit Website →

Want to dig deeper into these stocks?